Newsroom

Mallinckrodt Pharmaceuticals Presented 15 Posters on Investigational Drug at PAINWeek 2013

LAS VEGAS--(BUSINESS WIRE)--Sep. 6, 2013-- Mallinckrodt (NYSE: MNK) presented 15 posters with data on its investigational drug, MNK-795, studied for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate, at PAINWeek, which runs from Sept. 4-7 in Las Vegas. The studies span the compound’s efficacy, safety, abuse-related characteristics, and release/delivery profile with immediate and extended-release components.

For more information about Mallinckrodt’s presence at PAINWeek, contact Mallinckrodt Medical Information at 1.800.788.7898 or by email.

“As a leader in pain management, Mallinckrodt has taken a comprehensive approach to driving research in the acute pain category,” said Tom Smith, M.D., Chief Medical Officer at Mallinckrodt. “We believe that the data presented this week show our commitment to this disease area.”

In addition, Mallinckrodt hosted a booth focused on the responsible delivery of opioid medications, a C.A.R.E.S. Alliance^SM booth, and a sponsored symposium titled “Regulatory Changes and Abuse Deterrence: Impact on Products and Practices.” Mallinckrodt is dedicated to providing medications for treatment of patients with pain, and is equally committed to working with policy makers, law enforcement, and industry to address the complex issues of abuse and diversion.

If you would like more information about PAINWeek, please click here.

ABOUT MALLINCKRODT:

Mallinckrodt is a leading global specialty pharmaceuticals business that develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents. The Company’s Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide with direct sales in roughly 50 countries and distribution in approximately 40 other countries. The Company’s 2012 revenue totaled $2.1 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

FORWARD-LOOKING STATEMENTS

Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future financial condition and operating results, economic, business, competitive and/or regulatory factors affecting our business. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or Company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, our ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration, our ability to obtain and/or timely transport molybdenum-99 to our technetium-99m generator production facilities, customer concentration, cost-containment efforts of customers, purchasing groups, third-party payors and governmental organizations, our ability to successfully develop or commercialize new products, our ability to protect intellectual property rights, competition, our ability to integrate acquisitions of technology, products and businesses, product liability losses and other litigation liability, the reimbursement practices of a small number of large public or private issuers, complex reporting and payment obligation under healthcare rebate programs, changes in laws and regulations, conducting business internationally, foreign exchange rates, material health, safety and environmental liabilities, litigation and violations and information technology infrastructure. These and other factors are identified and described in more detail in the “Risk Factors” section of the Form 10 Registration Statement, as amended. We disclaim any obligation to update these forward-looking statements other than as required by law.

Source: Mallinckrodt

Mallinckrodt
Lynn Phillips, 314-654-3263
Manager, Media Relations
lynn.phillips@mallinckrodt.com
or
Meredith Fischer, 314-654-6595
Senior Vice President, Communications
meredith.fischer@mallinckrodt.com
or
John Moten, 314-654-6650
Vice President, Investor Relations
john.moten@mallinckrodt.com